Hoth Therapeutics Beheer
Beheer criteriumcontroles 3/4
Hoth Therapeutics' CEO is Robb Knie, appointed in May 2017, has a tenure of 7.5 years. total yearly compensation is $868.82K, comprised of 51.8% salary and 48.2% bonuses, including company stock and options. directly owns 0.84% of the company’s shares, worth $49.99K. The average tenure of the management team and the board of directors is 5.7 years and 4.8 years respectively.
Belangrijke informatie
Robb Knie
Algemeen directeur
US$868.8k
Totale compensatie
| Percentage CEO-salaris | 51.8% |
| Dienstverband CEO | 7.5yrs |
| Eigendom CEO | 0.8% |
| Management gemiddelde ambtstermijn | 5.7yrs |
| Gemiddelde ambtstermijn bestuur | 4.8yrs |
Recente managementupdates
Recent updates
Hoth Therapeutics partners with Altasciences to manufacture HT-TBI for brain injury
Sep 20Hoth Therapeutics granted grace days by Nasdaq to regain compliance with bid price rule
Jun 29Here's Why We're Watching Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Situation
Nov 12
Hoth Therapeutics extends agreement for experimental antibiotic
Jun 18We're Not Very Worried About Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Rate
Jun 10Hoth Therapeutics expands research agreement with VCU for COVID-19 therapeutic
May 05Hoth Therapeutics shares rise 10% on developmental plans for HT-KIT in multiple orphan diseases and rare cancers
May 03Hoth provides pipeline and regulatory timeline update
Feb 02FDA grants Hoth Therapeutics Pre-IND meeting for HT-001, shares up 15%
Jan 13Hoth Therapeutics to initiate IND enabling studies of HT-001 in cancer
Jan 11Hoth Therapeutics inks deal for treatment of multi-drug resistant bacterial lung infections, shares up 15%
Jan 04Hoth therapeutics signs production agreement for HT-001, Shares up 75%
Dec 31Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$7m |
| Mar 31 2024 | n/a | n/a | -US$8m |
| Dec 31 2023 | US$869k | US$450k | -US$8m |
| Sep 30 2023 | n/a | n/a | -US$10m |
| Jun 30 2023 | n/a | n/a | -US$10m |
| Mar 31 2023 | n/a | n/a | -US$11m |
| Dec 31 2022 | US$1m | US$450k | -US$11m |
| Sep 30 2022 | n/a | n/a | -US$11m |
| Jun 30 2022 | n/a | n/a | -US$12m |
| Mar 31 2022 | n/a | n/a | -US$13m |
| Dec 31 2021 | US$1m | US$400k | -US$14m |
| Sep 30 2021 | n/a | n/a | -US$12m |
| Jun 30 2021 | n/a | n/a | -US$10m |
| Mar 31 2021 | n/a | n/a | -US$10m |
| Dec 31 2020 | US$781k | US$350k | -US$7m |
| Sep 30 2020 | n/a | n/a | -US$10m |
| Jun 30 2020 | n/a | n/a | -US$10m |
| Mar 31 2020 | n/a | n/a | -US$9m |
| Dec 31 2019 | US$2m | US$350k | -US$8m |
| Sep 30 2019 | n/a | n/a | -US$4m |
| Jun 30 2019 | n/a | n/a | -US$3m |
| Mar 31 2019 | n/a | n/a | -US$3m |
| Dec 31 2018 | US$308k | US$250k | -US$2m |
| Sep 30 2018 | n/a | n/a | -US$3m |
| Dec 31 2017 | US$146k | US$146k | -US$3m |
Compensatie versus markt: Robb's total compensation ($USD868.82K) is above average for companies of similar size in the US market ($USD655.65K).
Compensatie versus inkomsten: Robb's compensation has been consistent with company performance over the past year.
CEO
Robb Knie (55 yo)
7.5yrs
Tenure
US$868,823
Compensatie
Mr. Robb Knie is Founder of Hoth Therapeutics, Inc. Mr. Knie served as the Chief Executive Officer, Chief Financial Officer and Chairman of the Board of Directors of FoxWayne Enterprises Acquisition Corp....
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 7.5yrs | US$868.82k | 0.84% $ 50.0k | |
| Chief Financial Officer | 5.7yrs | geen gegevens | geen gegevens | |
| Executive Vice President of Operations | 2.5yrs | geen gegevens | geen gegevens |
5.7yrs
Gemiddelde duur
Ervaren management: HOTH's management team is seasoned and experienced (5.7 years average tenure).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 7.5yrs | US$868.82k | 0.84% $ 50.0k | |
| Member of Scientific Advisory Board | 7.3yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 3.8yrs | geen gegevens | geen gegevens | |
| Independent Director | 6.3yrs | US$65.21k | 0.014% $ 859.7 | |
| Member of Scientific Advisory Board | 4.9yrs | geen gegevens | geen gegevens | |
| Independent Director | 4.6yrs | US$65.21k | 0.0019% $ 115.2 | |
| Member of Scientific Advisory Board | 4.8yrs | geen gegevens | geen gegevens | |
| Independent Director | 4.8yrs | US$65.21k | 0.018% $ 1.1k | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 1.9yrs | US$65.21k | 0.074% $ 4.4k | |
| Member of Scientific Advisory Board | 2.8yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 2.8yrs | geen gegevens | geen gegevens |
4.8yrs
Gemiddelde duur
56yo
Gemiddelde leeftijd
Ervaren bestuur: HOTH's board of directors are considered experienced (4.8 years average tenure).